SK Bioscience Rises on News of EU GMP Certification for COVID-19 Vaccine Factory
[Asia Economy Reporter Ji Yeon-jin] On the 17th, SK Bioscience showed strong performance following the news that its Andong plant, which produces COVID-19 vaccines, received European quality management standard certification.
As of 10:30 AM on the same day, SK Bioscience was trading at 156,500 KRW on the KOSPI market, up 7.19% compared to the previous trading day.
The company announced on the 17th that it had obtained EU GMP (Good Manufacturing Practice) certification for the contract manufacturing of COVID-19 vaccines. GMP is a system that certifies strict management standards applied to all processes from raw material procurement to manufacturing, quality control, and shipment to ensure the production of high-quality pharmaceuticals.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
SK Bioscience evaluated that acquiring EU-GMP certification has established a foundation for entering the European market with the COVID-19 vaccines it is contract manufacturing. The company also plans to prepare for US cGMP certification in the future.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
